We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Langwirksame Beta-2-Sympathomimetika in der pädiatrischen Asthmatherapie - Freund oder Feind?
- Authors
Kurz, Herbert; Eber, Ernst; Frischer, Thomas; Götz, Manfred; Horak, Elisabeth; Riedler, Josef; Schmitzberger, Rudolf; Zach, Maximilian
- Abstract
Recent publications suggest that long-acting beta-2 agonists (LABAs) increase the risk for death in asthma. The American Food and Drug Administration (FDA) published a relevant alert in 2005. In the currently valid Austrian consensus guidelines for drug therapy of bronchial asthma in children and adolescents, LABAs are only recommended as add-on therapy in those patients whose asthma is not sufficiently controlled by inhaled corticosteroids (ICS) alone. LABAs have no established role in earlier steps of the therapeutic algorithm; consequently, the prescription of ICS-LABA combinations for initial treatment of paediatric asthma is not supported by these consensus treatment guidelines.
- Publication
Wiener Klinische Wochenschrift, 2006, Vol 118, Issue 11/12, p362
- ISSN
0043-5325
- Publication type
Article
- DOI
10.1007/s00508-006-0607-0